Depo-Provera is a popular birth control option for thousands of women, especially in the United States. Since its FDA approval in 1992, it has been marketed as a highly convenient and reliable contraceptive.
However, in the case of Depo-Provera, the omission of key information has exposed many to severe risks in the form of meningiomas, a kind of tumor that is found in the brain and spinal cord.
Pfizer, the manufacturer of Depo-Provera, failed to disclose such information, leading to a large-scale legal battle, with cases expected to rise in 2025.
A British Medical Journal (BMJ) study in 2024 raised serious concerns about Depo-Provera's safety as a contraceptive. As stated in the BMJ research, those who use Depo-Provera are 5.5 times more likely to develop meningiomas than those not taking the medication at all.
While Pfizer admittedly knew about the risks, it only issued safety warnings about meningiomas in Europe and Canada, leaving U.S. consumers uninformed of its potential dangers. The inconsistency in Pfizer's transparency sparked allegations of corporate negligence.
Over 25% of women in the U.S. have used Depo-Provera. This considerably emphasizes the large number of people affected by its life-altering side effects. Now, women diagnosed with meningiomas connected to Depo-Provera use are experiencing the financial burden of having the disease.
Patients diagnosed with meningiomas require medical treatments that are not cheap. These include surgeries to remove tumors and radiation therapy to prevent their recurrence. Medical treatment costs can quickly accumulate, and many patients may not have the financial capacity to afford their medical care in the long run.
In addition to spending on healthcare, patients will also need time off to get treated, which leads to lost wages. Moreover, meningiomas can affect a person's ability to work and make a living. These tumors can significantly affect brain function, vision, and motor skills.
Ongoing lawsuits allege that Pfizer failed to warn U.S. consumers about the risks of Depo-Provera despite issuing proper warnings in Europe and Canada. People who continue to join the legal battle seek rightful compensation for medical expenses, lost wages, and the drug's long-term effects.
A Multidistrict Litigation (MDL) is set to begin in 2025. These legal proceedings will have about 30,000 cases fighting for Pfizer's responsibility for failing to disclose crucial safety information.
Depo-Provera's risks should never have been kept in the dark. If you are one of the thousands who have been diagnosed with meningioma after using Depo-Provera, you deserve justice and compensation. Don't wait; file a Depo-Provera claim for meningioma with the help of Atraxia Law today.